Aripiprazole for the Prevention of Relapse in Stabilized Patients With Chronic Schizophrenia

Pigott, Teresa A.; Carson, William H.; Saha, A.; Torbeyns, A.; Stock, E.; Ингенито, Г.

doi:10.4088/jcp.v64n0910

Cited by 293 publications

(199 citation statements)

References 0 publications

Supporting

Mentioning

179

Contrasting

Unclassified

Order By: Relevance

“…A 52-week, double-blind comparison study (58) involving 1,294 acute, relapsing patients demonstrated that, compared to haloperidol (10 mg/day), patients on aripiprazole (30 mg/day) demonstrated significant improvement in PANNS negative scores and in depressive symptoms as measured by Montgomery-Åsburg Depression Rating Scale (MADRS) scores. Time to relapse was similar for both groups (5,45,68). These results indicate the sustained efficacy of aripiprazole in stabilized patients with chronic schizophrenia.…”

Section: Schizophrenia and Related Disorderssupporting

confidence: 54%

See 1 more Smart Citation

Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology

2004

View full text Add to dashboard Cite

Aripiprazole (Abilify ® ) is an atypical antipsychotic drug that has been recently introduced for clinical use in the treatment of schizophrenia. Aripiprazole has a unique pharmacologic profile that includes partial agonism at several G-protein coupled receptors (GPCRs) [especially dopamine (D 2 ) and 5-HT 1A ] and antagonistic action at others (especially 5-HT 2A ). Clinical trials indicate that aripiprazole is effective in treating the positive and negative symptoms of schizophrenia. In short-term studies rapid onset of action (within one week) has been demonstrated. Preliminary data indicate that aripiprazole may also be effective in the treatment of manic symptoms of bipolar disorder. At recommended doses, aripiprazole appears to be safe and well tolerated in most adult patients with schizophrenia and schizoaffective disorder. There is only limited information available on the use of aripiprazole in children and adolescents, and pilot data suggest that a revised dosing strategy, based on weight, is indicated in this population. In the long-term studies, the use of aripiprazole was associated with continued efficacy, good compliance and increased time-to-relapse.Aripiprazole represents the first functionally selective atypical antipsychotic drug.

show abstract

Section: Schizophrenia and Related Disorderssupporting

confidence: 54%

“…Data from two studies (18,45,58,68) were used to evaluate the longer-term (26 and 52 weeks) efficacy of aripiprazole. In a placebo-controlled study of 310 outpatients with chronic, stable schizophrenia, Carson et al (18) examined the effects of aripiprazole treatment over a 26 week period.…”

Section: Schizophrenia and Related Disordersmentioning

confidence: 99%

Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology

2004

View full text Add to dashboard Cite

show abstract

“…We described an increase on QTc interval after the administration of aripiprazole. In a study with psychiatric patients the QTc interval decreased 6.94 ms from baseline to the end of treatment (40). Another study reported a reduction in QTc with aripiprazole (41).…”

Section: Pharmacodynamicsmentioning

confidence: 98%

Evaluation of the Relationship Between Pharmacokinetics and the Safety of Aripiprazole and Its Cardiovascular Effects in Healthy Volunteers

Belmonte¹,

Ochoa²,

Román³

et al. 2016

J Clin Psychopharmacol

View full text Add to dashboard Cite

Esta es la versión de autor del artículo publicado en: This is an author produced version of a paper published in: El acceso a la versión del editor puede requerir la suscripción del recurso Access to the published version may require subscription Aripiprazole treatment produced a decrease of blood pressure (9.3 mmHg on systolic and 6.2 mmHg on diastolic pressure) and an increase in heart rate (12.1 bpm) and QTc interval (9.1 ms). There were sex differences in blood pressure, heart rate and QTc interval.Women and subjects with higher AUC and Cmax values were more prone to suffer adverse drug reactions (ADRs) and gastrointestinal adverse reactions. AUC was related with systolic blood pressure (SBP) and diastolic blood pressure (DBP) decrease and heart rate (HR) increase but there was no relationship between aripiprazole concentrations and QTc increase.Conclusions -Aripiprazole decreases blood pressure and increases heart rate and QTc interval. Pharmacokinetics, pharmacodynamics and safety of aripiprazole are affected by sex. There is a directly proportional relationship between pharmacokinetic parameters and ADRs and effect on BP and HR.

show abstract

“…We made a sensitivity analysis excluding studies that consisted of patients with predominantly negative symptoms, [18][19][20][21][22][23] long-term studies on initially stable patients [24][25][26][27][28] and one very short study of only 2 weeks duration. 29 Owing to space limitations, we do not show the results here, but any result that deviated to an important extent from the primary analysis will be mentioned.…”

Section: Meta-analytic Calculationsmentioning

confidence: 99%

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

et al. 2008

View full text Add to dashboard Cite

We conducted a systematic review and meta-analysis of randomized controlled trials that compared second-generation antipsychotic (SGA) drugs with placebo in schizophrenic patients and which considered 13 different outcome measures. Thirty-eight randomized controlled trials with 7323 participants were included. All SGA drugs were more effective than placebo, but the pooled effect size (ES) for overall symptoms (primary outcome) was moderate (À0.51). The absolute difference (RD) in responder rates was at 18% (41% responded to drug compared with 24% to placebo, number needed to treat = 6). Similar ESs were found for the other efficacy parameters: negative symptoms (ES = À0.39), positive symptoms (ES = À0.48), depression (ES = À0.26), relapse (RD 20%) and discontinuation due to inefficacy (RD 17%). Curiously, the efficacy of haloperidol for negative and depressive symptoms was similar to that of the SGA drugs. In contrast to haloperidol, there was no difference in terms of EPS between any SGA drugs and placebo, and there was also no difference in terms of dropouts due to adverse events. Meta-regression showed a decline in treatment response over time, and a funnel plot suggested the possibility of publication bias. We conclude that the drug versus placebo difference of SGA drugs and haloperidol in recent trials was moderate, and that there is much room for more efficacious compounds. Whether methodological issues account in part for the relatively low efficacy ESs and the scarcity of adverse event differences compared with placebo needs to be established.

show abstract

Aripiprazole for the Prevention of Relapse in Stabilized Patients With Chronic Schizophrenia

Cited by 293 publications

References 0 publications

Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology

Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology

Evaluation of the Relationship Between Pharmacokinetics and the Safety of Aripiprazole and Its Cardiovascular Effects in Healthy Volunteers

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

Contact Info

Product

Resources

About